Read Editorial with D2G – Ep 499

Read Editorial with D2G – Ep 499

Return to frontpage

Gearing up: On vaccines and public trust

D2G wears no responsibility of the views published here by the respective Author. This Editorial is used here for Study Purpose. Students are advised to learn the word-meaning, The Art of Writing Skills and understand the crux of this Editorial.

Read Editorial

Meanings are given in BOLD

India now has a firm ( having a solid, almost unyielding surface or structure ) date to roll out the biggest vaccination programme in its history. Prime Minister Narendra Modi has said that from January 16, after the Makar Sankranti and Pongal festivities, doctors, nurses and sanitation workers, who are part of the priority group, would begin getting the vaccine. India has approved two vaccines in emergency-use mode — Covishield by the Serum Institute of India, Pune, and Covaxin by Bharat Biotech Ltd.

While it still is unclear who gets which vaccine, there are more doses of Covishield available at present than Covaxin, almost five to one, and it could take a few months before the 30 million prioritised ( to put tasks, problems, etc. in order of importance, so that you can deal with the most important first ) get one of their doses. Others, those in the 50-plus age group and those with comorbidities ( more than one illness or disease occurring in one person at the same time ), will have to wait much longer, especially in a situation where vaccines such as those by Pfizer and Moderna are not made available for import by the private sector.

However, the vaccination begins under a cloud. Covaxin belongs to a league ( A league is a group of people, clubs, or countries that have joined together for a particular purpose ) of vaccines that has been approved without establishing its efficacy ( Efficacy is a more formal way to say effectivenes ), namely, the extent to which vaccination protects from COVID-19.

There have been differences among scientists such as on the best testing strategy, treatment, extent of infection, but none more divisive ( likely to cause disagreements or arguments between people ) than on the approval of Covaxin. Several experts have made the case that the declining rate of infections and low relative mortality meant that India was not in as dire ( very bad or serious; terrible ) a state of emergency that required it to approve an untested vaccine when more clarity would likely have come by March.

Covaxin is best kept as a backup in the event of a sudden surge ( a sudden strong movement in a particular direction by a large number of people or things ) of cases till its efficacy data are available and acceptable. Also, reports have emerged of trials in Bhopal where volunteers were seemingly under the impression that they were getting a protective shot when some were likely getting a placebo ( A placebo is used in clinical trials to test the effectiveness of treatments and is most often used in drug studies).

They also complain of no medical follow-up when some developed symptoms such as fever, body pain and loss of appetite. The vaccine may eventually prove protective and the adverse symptoms reported, seen as part of the variety of the human body’s response — there are 28,500 volunteers after all. However, a vaccine that evokes ( to produce a memory, feeling, etc. in somebody ) distrust is self-defeating. With childhood immunisation, India has proven that it has the infrastructural backbone to inoculate ( to introduce one thing into another so as to affect it throughout ) millions.

The dry runs to test the Co-WIN management software have reportedly given authorities valuable feedback on perfecting the prospective rollout ( to introduce (something, such as a new product) especially for widespread sale to the public ). However, this could be undone if people do not turn up, and worse, if vaccine hesitancy ( the quality or state of being hesitant ; doubt ) rises.

The pandemic gave India an opportunity to examine its dispensation (exemption from a rule or usual requirement) of health care. Along with improving access, the government must seriously examine the conduct of vaccine trials and work hard to bolster ( support or strengthen ) public trust in it, and monitor the vaccination process for adverse ( preventing success or development; harmful; unfavourable ) reactions.

Check out our latest videos on youtube